Cargando…
DOACs in Patients With Giant Coronary Artery Aneurysms After Kawasaki Disease
This case series examines outcomes among patients with giant coronary artery aneurysms after Kawasaki disease treated with direct oral anticoagulants (DOACs).
Autores principales: | Dummer, Kirsten B., Miyata, Koichi, Shimizu, Chisato, Tremoulet, Adriana H., Gleason, Jill, Gordon, John B., Burns, Jane C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638650/ https://www.ncbi.nlm.nih.gov/pubmed/37948083 http://dx.doi.org/10.1001/jamanetworkopen.2023.43801 |
Ejemplares similares
-
Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis
por: Miyata, Koichi, et al.
Publicado: (2023) -
Exercise Stress Echocardiography in Kawasaki Disease Patients with Coronary Aneurysms
por: Tedla, Bruke A., et al.
Publicado: (2022) -
Biomarkers of inflammation and fibrosis in young adults with history of Kawasaki disease()
por: Hoshino, Shinsuke, et al.
Publicado: (2021) -
Biomarkers of Inflammation and Fibrosis in Kawasaki Disease Patients Years After Initial Presentation With Low Ejection Fraction
por: Hoshino, Shinsuke, et al.
Publicado: (2019) -
Identification of novel locus associated with coronary artery aneurysms and validation of loci for susceptibility to Kawasaki disease
por: Hoggart, Clive, et al.
Publicado: (2021)